Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]-N188
- Development stage
- Unknown
- Lead developer
- Peking University First Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Cyclic Peptides → Modified Peptides → Peptides
- Administration
- Intravenous
01
Overview
[68Ga]-N188 is an investigational positron emission tomography (PET) radiotracer designed for noninvasive imaging of Nectin-4 expression in solid tumors. Developed by researchers at Peking University First Hospital, the agent consists of a high-affinity bicyclic peptide ligand (N188) derived from the BT8009 scaffold, conjugated to the positron-emitting radionuclide gallium-68 (68Ga). N188 binds specifically to Nectin-4 (nectin cell adhesion molecule 4), a transmembrane protein overexpressed in urothelial carcinoma and various other epithelial malignancies, including pancreatic, breast, lung, and ovarian cancers. By quantifying membranous Nectin-4 expression, [68Ga]-N188 PET/CT imaging serves as a potential companion diagnostic tool to select and stratify patients for Nectin-4-targeted therapies, such as the antibody-drug conjugate enfortumab vedotin.
- Other names
- Gallium-68-N188Gallium68-N188Gallium 68-N188
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on [68Ga]-N188.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]-N188.